A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis

A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis

Current therapies for anthrax include the use of antibiotics (i.e., doxycycline, and ciprofloxacin), an anthrax vaccine (BioThrax) and Bacillus anthracis-specific, monoclonal antibody (mAb) (i.e., Raxibacumab and obiltoxaximab). In this study, we investigated the activity of immunomodulators, which...

Full description

Bibliographic Details
Main Authors: Chih-Yuan Chiang, Douglas J. Lane, Yefen Zou, Tim Hoffman, Jianfeng Pan, Janice Hampton, Jillian Maginnis, Bishnu P. Nayak, Ugo D’Oro, Nicholas Valiante, Andrew T. Miller, Michael Cooke, Tom Wu, Sina Bavari, Rekha G. Panchal
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Microbiology
Subjects:
TLR2
agonist
Bacillus anthracis
in vivo
prophylactic
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2022.803041/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2022.803041/full

Similar Items